Skip to main content
 CHANGE IN VISITATION GUIDELINES: Please read before visiting Rutgers Cancer Institute.
Menu

Print this page

BTCRC-LUN16-081: Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab alone following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC).

Primary Objective:
To determine if consolidation therapy with nivolumab plus ipilimumab or nivolumab alone following concurrent chemoradiation improves 18-month progression free survival (PFS) in subjects with inoperable or unresectable stage IIIA or IIIB NSCLC.

Secondary Objectives:
1) To determine if consolidation therapy with nivolumab plus ipilimumab or nivolumab alone following concurrent chemoradiation improves time to metastatic disease and overall survival (OS) in subjects with inoperable or unresectable stage IIIA or IIIB NSCLC.
2) hTo assess toxicity and tolerability of consolidation therapy with nivolumab plus ipilimumab or nivolumab alone following concurrent chemoradiation in subjects with inoperable or unresectable stage IIIA or IIIB NSCLC.

Protocol Number: 031706
Phase: Phase II
Applicable Disease Sites: Lung
Drugs Involved: Opdivo (Nivolumab)
IPILIMUMAB (MDX-010)
Principal Investigator: Salma Jabbour M.D.
Scope: National
Therapies Involved: Chemotherapy single agent systemic
Chemotherapy multiple agents systemic
Participating Institutions:
  • Rutgers Cancer Institute of New Jersey
    • Principal Investigator
      • Salma Jabbour M.D.
Inclusion & Exclusion Criteria

Please note that we have obtained the inclusion and exclusion criteria information from the National Institutes of Health’s clinical trials web site www.clinicaltrials.gov. The listed criteria may not necessarily reflect recent amendments to the protocol and the current criteria. For additional information on this trial or other available clinical trials please contact the research nurse.

For further information about clinical trials, please contact us at 732-235-7356.